Month: February 2025

Innovative Licensing and Access Pathway The UK has launched a refreshed Innovative Licensing and Access Pathway (ILAP) to expedite the delivery of transformative medicines to patients in the NHS. This pathway, unique globally, allows medicine developers to collaborate with the national health system, regulators, and health technology assessment bodies from early clinical development stages. Key… Continue reading Innovative Licensing and Access Pathway

Strategic Agenda for FDA‘s rare disease, innovation hub The FDA’s Rare Disease Innovation Hub has released its Strategic Agenda, focusing on advancing regulatory science of rare disease therapies, strengthening coordination between FDA’s Medical Product Centers, and creating a centralized point of contact for external partners. #FDA #RareDisease #StrategicAgenda #Innovation #Hub